Literature DB >> 1068516

The pharmacokinetics of ketoprofen in man during and after repeated oral dosing (50 mg q.i.d.) with Orudis.

O R Lewellen, R Templeton.   

Abstract

The pharmacokinetics of ketoprofen were studied in 5 healthy male volunteers after the oral administration of Orudis as a single dose (50 mg) and during, and after a 24-day repeated dosing regimen (50 mg q.i.d.). Levels of ketoprofen in plasma and urine and of conjugated ketoprofen in urine were measured after extraction, by a gas-liquid chromatographic method, which involved the use of a structurally similar internal standard. The minimum level of detection of the method was 40 ng ketoprofen/ml of plasma or 20 ng ketoprofen/ml of urine. The pharmacokinetic parameters obtained following a single oral dose, were comparable with those obtained in previous studies with human subjects from Britain, America and France. Repeated oral administration of a therapeutically effective dose of Orudis (50 mg q.i.d.), resulted in the rapid attainment of a plateau plasma level of ketoprofen, which was maintained throughout the course of dosing. Ketoprofen plasma levels and urinary clearance after the final dose of the 24-day repeated oral dosing regimen, were more variable and generally lower than those found following a single oral dose. However, the early plasma half-lives for the two experiments were similar. It was concluded that in the initial stages of repeated dosing a reduction in ketoprofen absorption, compared to that found after a single oral dose, occurred, and resulted in lower plasma levels of drug.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1068516

Source DB:  PubMed          Journal:  Scand J Rheumatol Suppl        ISSN: 0301-3847


  7 in total

1.  Circadian changes in the pharmacokinetics of oral ketoprofen.

Authors:  M Ollagnier; H Decousus; Y Cherrah; F Levi; M Mechkouri; P Queneau; A Reinberg
Journal:  Clin Pharmacokinet       Date:  1987-05       Impact factor: 6.447

2.  Pharmacokinetic profile of controlled release ketoprofen in elderly patients.

Authors:  M J Dennis; P C French; P Crome; M Babiker; J Shillingford; R Hopkins
Journal:  Br J Clin Pharmacol       Date:  1985-12       Impact factor: 4.335

3.  Pharmacokinetics of ketoprofen following single oral, intramuscular and rectal doses and after repeated oral administration.

Authors:  T Ishizaki; T Sasaki; T Suganuma; Y Horai; K Chiba; M Watanabe; W Asuke; H Hoshi
Journal:  Eur J Clin Pharmacol       Date:  1980-11       Impact factor: 2.953

Review 4.  Clinical pharmacokinetics of ketoprofen and its enantiomers.

Authors:  F Jamali; D R Brocks
Journal:  Clin Pharmacokinet       Date:  1990-09       Impact factor: 6.447

5.  Ketoprofen pharmacokinetics and bioavailability based on an improved sensitive and specific assay.

Authors:  R A Upton; R L Williams; T W Guentert; J N Buskin; S Riegelman
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

6.  Clinical pharmacokinetics of ketoprofen after single intravenous administration as a bolus or infusion.

Authors:  D Debruyne; B Hurault de Ligny; J P Ryckelynck; F Albessard; M Moulin
Journal:  Clin Pharmacokinet       Date:  1987-03       Impact factor: 6.447

Review 7.  Clinical pharmacokinetics of non-steroidal anti-inflammatory drugs.

Authors:  R K Verbeeck; J L Blackburn; G R Loewen
Journal:  Clin Pharmacokinet       Date:  1983 Jul-Aug       Impact factor: 6.447

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.